Date,Articles
2014-03-27,"{""abstract"": ""In the wake of Baxter\u2019s split, Merck, Bayer and Johnson & Johnson may find it hard not to jump on the bandwagon, says Robert Cyran of Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/03/27/conscious-uncoupling-for-drug-makers/"", ""snippet"": ""In the wake of Baxter\u2019s split, Merck, Bayer and Johnson & Johnson may find it hard not to jump on the bandwagon, says Robert Cyran of Reuters Breakingviews."", ""lead_paragraph"": ""Baxter International has put conscious uncoupling on pharma\u2019s radar."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/28/business/dbpix-baxter2/dbpix-baxter2-jumbo.jpg"", ""height"": 374, ""width"": 523, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/28/business/dbpix-baxter2/dbpix-baxter2-superJumbo.jpg"", ""height"": 374, ""width"": 523, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/28/business/dbpix-baxter2/dbpix-baxter2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/03/28/business/dbpix-baxter2/dbpix-baxter2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/28/business/dbpix-baxter2/dbpix-baxter2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Conscious Uncoupling for Drug Makers"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Biotechnology"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baxter International"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-03-27T18:42:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/dffcc012-2fc0-597c-8c34-95bbdf1e8405"", ""word_count"": 354, ""uri"": ""nyt://article/dffcc012-2fc0-597c-8c34-95bbdf1e8405""}"
2014-05-01,"{""abstract"": ""The big health care company, is close to a deal to sell its consumer unit to Bayer for about $14 billion, a person briefed on the matter said on Thursday."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/01/bayer-nears-deal-for-merck-consumer-unit/"", ""snippet"": ""The big health care company, is close to a deal to sell its consumer unit to Bayer for about $14 billion, a person briefed on the matter said on Thursday."", ""lead_paragraph"": ""Updated, 8:01 p.m. | Merck, the big health care company, is close to a deal to sell its consumer unit to Bayer for about $14 billion, a person briefed on the matter said on Thursday."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""height"": 663, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 663}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-jumbo.jpg"", ""height"": 1024, ""width"": 927, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-superJumbo.jpg"", ""height"": 1760, ""width"": 1592, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-merck/dbpix-merck-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck Said to Be Near Closing Deal With Bayer"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Merck Said To Be Near Closing Deal With Bayer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bayer AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-05-01T22:39:26+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/323dfe19-da70-578a-ad29-aeada6e33acb"", ""word_count"": 393, ""uri"": ""nyt://article/323dfe19-da70-578a-ad29-aeada6e33acb""}"
2014-05-06,"{""abstract"": ""Bayer\u2019s $14.2 billion acquisition of Merck\u2019s consumer care business makes strategic sense and sizable tax breaks will help, writes Olaf Storbeck of Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/06/how-bayers-buy-makes-sense/"", ""snippet"": ""Bayer\u2019s $14.2 billion acquisition of Merck\u2019s consumer care business makes strategic sense and sizable tax breaks will help, writes Olaf Storbeck of Reuters Breakingviews."", ""lead_paragraph"": ""Bayer\u2019s $14.2 billion acquisition of Merck\u2019s consumer care business is less pricey than it looks."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-articleLarge.jpg"", ""height"": 365, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 365}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-jumbo.jpg"", ""height"": 622, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-superJumbo.jpg"", ""height"": 1244, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-bayer2/dbpix-bayer2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""How Bayer\u2019s Buy Makes Sense"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Credits, Deductions and Exemptions"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bayer AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-06T20:10:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Olaf Storbeck"", ""person"": [{""firstname"": ""Olaf"", ""middlename"": null, ""lastname"": ""Storbeck"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ace912f3-f982-51bf-826d-67f3073c7b64"", ""word_count"": 364, ""uri"": ""nyt://article/ace912f3-f982-51bf-826d-67f3073c7b64""}"
2014-06-09,"{""abstract"": ""Merck will pay $24.50 a share in cash, or about $3.85 billion, for the biotechnology company Idenix in an effort to bolster its arsenal of potential drugs in the hotly competitive hepatitis C area."", ""web_url"": ""https://dealbook.nytimes.com/2014/06/09/merck-to-acquire-idenix-pharmaceuticals/"", ""snippet"": ""Merck will pay $24.50 a share in cash, or about $3.85 billion, for the biotechnology company Idenix in an effort to bolster its arsenal of potential drugs in the hotly competitive hepatitis C area."", ""lead_paragraph"": ""Updated, 8:32 p.m. | Merck will buy the biotechnology company Idenix Pharmaceuticals for $3.85 billion in an effort to bolster its arsenal of potential drugs in the competitive arena of hepatitis C treatments, the companies announced on Monday."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/10/business/Merck/Merck-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/06/10/business/Merck/Merck-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/10/business/Merck/Merck-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/10/business/Merck/Merck-superJumbo.jpg"", ""height"": 853, ""width"": 1280, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/10/business/Merck/Merck-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/06/10/business/Merck/Merck-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/10/business/Merck/Merck-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck Bids $3.8 Billion for an Edge in Hepatitis"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Merck Bids $3.8 Billion for an Edge in Hepatitis"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sovaldi (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Idenix Pharmaceuticals Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-06-09T11:42:40+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4ac748bf-67e9-5ea0-8ee7-c1df0b20c885"", ""word_count"": 869, ""uri"": ""nyt://article/4ac748bf-67e9-5ea0-8ee7-c1df0b20c885""}"
2014-09-04,"{""abstract"": ""The treatment unleashes the body\u2019s immune system against tumors, and will initially be used against advanced melanoma."", ""web_url"": ""https://www.nytimes.com/2014/09/05/business/merck-wins-approval-of-novel-immune-system-drug-for-cancer.html"", ""snippet"": ""The treatment unleashes the body\u2019s immune system against tumors, and will initially be used against advanced melanoma."", ""lead_paragraph"": ""The Food and Drug Administration on Thursday approved the first of an eagerly awaited new class of cancer drugs that unleashes the body\u2019s immune system to fight tumors."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/05/business/Drug/Drug-articleLarge.jpg"", ""height"": 567, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/09/05/business/Drug/Drug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 567}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/05/business/Drug/Drug-jumbo.jpg"", ""height"": 967, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/05/business/Drug/Drug-superJumbo.jpg"", ""height"": 1305, ""width"": 1382, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/05/business/Drug/Drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/09/05/business/Drug/Drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/05/business/Drug/Drug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""F.D.A. Allows First Use of a Novel Cancer Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Allows First Use of a Novel Cancer Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Immune System"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Melanomas"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-09-04T20:40:23+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/94af2b85-6573-5807-8017-f4f8f6a8f6d3"", ""word_count"": 1074, ""uri"": ""nyt://article/94af2b85-6573-5807-8017-f4f8f6a8f6d3""}"
2014-09-22,"{""abstract"": ""A rare bright spot in the European economy in recent years, many of the biggest German companies have begun capitalizing on their strength, striking big deals for overseas competitors."", ""web_url"": ""https://dealbook.nytimes.com/2014/09/22/german-companies-continue-their-buying-spree/"", ""snippet"": ""A rare bright spot in the European economy in recent years, many of the biggest German companies have begun capitalizing on their strength, striking big deals for overseas competitors."", ""lead_paragraph"": ""Germany\u2019s businesses have been the rare bright spot in the European economy in recent years, generating jobs and profits even as neighboring countries face persistent unemployment."", ""print_section"": ""B"", ""print_page"": ""9"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/23/business/LIFE/LIFE-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/09/23/business/LIFE/LIFE-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/23/business/LIFE/LIFE-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/23/business/LIFE/LIFE-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/23/business/LIFE/LIFE-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/09/23/business/LIFE/LIFE-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/23/business/LIFE/LIFE-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Cash-Stuffed German Companies on a Global Buying Spree"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Cash-Stuffed German Companies on a Global Buying Spree"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Economic Conditions and Trends"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Dresser-Rand Group Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck of Germany"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Siemens AG"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sigma-Aldrich Corporation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Germany"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-09-22T16:18:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c31184af-f19c-54d3-b9f9-6c80281b4798"", ""word_count"": 1086, ""uri"": ""nyt://article/c31184af-f19c-54d3-b9f9-6c80281b4798""}"
2014-10-27,"{""abstract"": ""The pharmaceutical company\u2019s earnings beat expectations, however, helped by sales of the diabetes drug Januvia and revenue in emerging markets."", ""web_url"": ""https://www.nytimes.com/2014/10/28/business/merck-reports-third-quarter-earnings.html"", ""snippet"": ""The pharmaceutical company\u2019s earnings beat expectations, however, helped by sales of the diabetes drug Januvia and revenue in emerging markets."", ""lead_paragraph"": ""The drug maker Merck said revenue dropped by 4 percent in the third quarter as sales of its vaccine for cervical cancer fell and other drugs encountered increased competition from generics. Still, the company\u2019s earnings, reported Monday, beat analysts\u2019 expectations."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Merck Sales Down 4%; Profit Beats Forecasts "", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Merck Sales Down 4%; Profit Beats Forecasts"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-10-27T16:00:41+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/aca69630-3b91-56e0-922b-386fd23eac82"", ""word_count"": 445, ""uri"": ""nyt://article/aca69630-3b91-56e0-922b-386fd23eac82""}"
2014-11-17,"{""abstract"": ""The alliance between the American and German companies is expected to strengthen Merck\u2019s oncology business in several important markets, including the United States."", ""web_url"": ""https://dealbook.nytimes.com/2014/11/17/pfizer-to-pay-up-to-2-9-billion-in-cancer-drug-deal-with-merck-of-germany/"", ""snippet"": ""The alliance between the American and German companies is expected to strengthen Merck\u2019s oncology business in several important markets, including the United States."", ""lead_paragraph"": ""LONDON \u2014 Merck of Germany said on Monday that the American drug giant Pfizer had agreed to pay $850 million upfront and as much as $2 billion later in a deal to jointly develop one of Merck\u2019s cancer drugs."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer to Pay up to $2.9 Billion in Cancer Drug Deal With Merck of Germany"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck of Germany"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Germany"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-11-17T10:32:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/33223746-b95c-55ec-8365-355da0986132"", ""word_count"": 415, ""uri"": ""nyt://article/33223746-b95c-55ec-8365-355da0986132""}"
2014-12-06,"{""abstract"": ""The deal would represent another multibillion-dollar health care transaction in a banner year for mergers and acquisitions in the industry."", ""web_url"": ""https://dealbook.nytimes.com/2014/12/05/merck-in-talks-to-acquire-drug-maker-cubist-for-more-than-7-billion/"", ""snippet"": ""The deal would represent another multibillion-dollar health care transaction in a banner year for mergers and acquisitions in the industry."", ""lead_paragraph"": ""Merck & Company, the big drug maker, is in talks to acquire the biopharmaceuticals company Cubist for more than $7 billion, according to people briefed on the matter."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/06/business/dbpix-merck/dbpix-merck-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck Said to Weigh Acquisition of Rival Drug Maker Cubist"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Merck Said to Weigh Acquisition of a Rival"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-12-06T00:01:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/62795514-c399-53d1-a39e-3c17aef1e82f"", ""word_count"": 724, ""uri"": ""nyt://article/62795514-c399-53d1-a39e-3c17aef1e82f""}"
2014-12-07,"{""abstract"": ""In two early stage studies, Bristol-Myers Squibb\u2019s nivolumab and Merck\u2019s pembrolizumab shrank tumors in patients with Hodgkin\u2019s lymphoma."", ""web_url"": ""https://www.nytimes.com/2014/12/07/business/cancer-drugs-that-free-brake-on-immune-system-show-promise-for-hodgkins.html"", ""snippet"": ""In two early stage studies, Bristol-Myers Squibb\u2019s nivolumab and Merck\u2019s pembrolizumab shrank tumors in patients with Hodgkin\u2019s lymphoma."", ""lead_paragraph"": ""Drugs that free the body\u2019s immune system to fight cancer have shown strong preliminary results in treating Hodgkin\u2019s lymphoma, shrinking tumors in well over half of patients who had exhausted many other treatment options, researchers reported on Saturday."", ""print_section"": ""A"", ""print_page"": ""30"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Cancer Drugs That Free Brake on Immune System Show Promise for Hodgkin\u2019s"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Cancer Drugs That Free Brake on Immune System Show Promise for Hodgkin\u2019s"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""New England Journal of Medicine"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hodgkin's Lymphoma"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-12-07T00:41:38+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/752a15eb-b75e-5860-b9cc-88591ffbbd6e"", ""word_count"": 606, ""uri"": ""nyt://article/752a15eb-b75e-5860-b9cc-88591ffbbd6e""}"
2014-12-08,"{""abstract"": ""Merck is paying only about 4.3 times Cubist\u2019s estimated revenue for next year \u2014 about the same multiple investors give Merck itself, making the acquisition look like a relative bargain, writes Robert Cyran of Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/12/08/revival-for-antibiotics-could-spur-deals/"", ""snippet"": ""Merck is paying only about 4.3 times Cubist\u2019s estimated revenue for next year \u2014 about the same multiple investors give Merck itself, making the acquisition look like a relative bargain, writes Robert Cyran of Reuters Breakingviews."", ""lead_paragraph"": ""Superbugs may have beneficial side effects \u2013 for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck is betting $8.4 billion that the antibiotics used to fight them will become more profitable."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/dbpix-merck/dbpix-merck-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Revival for Antibiotics Could Spur Deals"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""ANTIBIOTICS"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cubist Pharmaceuticals Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-12-08T19:39:29+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/31c7ecfb-55f6-5a0e-920a-74533c0228df"", ""word_count"": 378, ""uri"": ""nyt://article/31c7ecfb-55f6-5a0e-920a-74533c0228df""}"
2014-12-09,"{""abstract"": ""Just hours after announcing its $8.4 billion acquisition of Cubist Pharmaceuticals, a Delaware judge invalidated patents owned by the antibiotics maker. Merck appears to have been caught up in the M.&.A. exuberance, says Robert Cyran of Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/12/09/mercks-rose-colored-deal-making/"", ""snippet"": ""Just hours after announcing its $8.4 billion acquisition of Cubist Pharmaceuticals, a Delaware judge invalidated patents owned by the antibiotics maker. Merck appears to have been caught up in the M.&.A. exuberance, says Robert Cyran of Reuters Br..."", ""lead_paragraph"": ""The M.&A. frenzy appears to have influenced Merck\u2019s risk assessment. Just hours after announcing its $8.4 billion acquisition of Cubist Pharmaceuticals on Monday, a judge invalidated patents owned by the antibiotics maker. Potential lost sales are reflected in the billions erased from Merck\u2019s market value."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/10/business/dbpix-merck2/dbpix-merck2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck\u2019s Rose-Colored Glasses in Cubist Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""ANTIBIOTICS"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Inventions and Patents"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cubist Pharmaceuticals Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-12-09T19:30:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d5fe4dae-9f6a-5f97-ad57-f29e4c91ba68"", ""word_count"": 369, ""uri"": ""nyt://article/d5fe4dae-9f6a-5f97-ad57-f29e4c91ba68""}"
2014-12-11,"{""abstract"": ""The hospital said it would halt injections of a vaccine licensed to Merck until next month, after some test subjects reported mild joint pain."", ""web_url"": ""https://www.nytimes.com/2014/12/12/business/geneva-hospital-pauses-test-of-an-ebola-vaccine.html"", ""snippet"": ""The hospital said it would halt injections of a vaccine licensed to Merck until next month, after some test subjects reported mild joint pain."", ""lead_paragraph"": ""A test of an experimental Ebola vaccine recently licensed to Merck has been temporarily paused after some vaccinated volunteers experienced pain in their joints, a medical center in Geneva announced on Thursday."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/12/business/Vaccine/Vaccine-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/12/12/business/Vaccine/Vaccine-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/12/business/Vaccine/Vaccine-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/12/business/Vaccine/Vaccine-superJumbo.jpg"", ""height"": 1364, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/12/business/Vaccine/Vaccine-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/12/12/business/Vaccine/Vaccine-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/12/business/Vaccine/Vaccine-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Hospital Pauses Test of an Ebola Vaccine Licensed to Merck"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Hospital Pauses Test of an Ebola Vaccine Licensed to Merck"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Ebola Virus"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Geneva (Switzerland)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Public Health Agency of Canada"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""NewLink Genetics Corporation"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Health and Human Services Department"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2014-12-11T19:58:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7a830d01-c74d-5cda-bd82-f45ee3298a56"", ""word_count"": 760, ""uri"": ""nyt://article/7a830d01-c74d-5cda-bd82-f45ee3298a56""}"
2015-01-23,"{""abstract"": ""Tests of drugs developed by GlaxoSmithKline and Merck are expected to begin in Liberia in two weeks, federal officials said."", ""web_url"": ""https://www.nytimes.com/2015/01/23/business/international/trial-of-2-ebola-vaccines-effectiveness-is-announced.html"", ""snippet"": ""Tests of drugs developed by GlaxoSmithKline and Merck are expected to begin in Liberia in two weeks, federal officials said."", ""lead_paragraph"": ""Federal officials said on Thursday that the first clinical trial to test the effectiveness of Ebola vaccines was expected to begin in Liberia in two weeks."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Trial of 2 Ebola Vaccines\u2019 Effectiveness Is Announced"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Ebola Virus"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Liberia"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2015-01-23T05:00:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a8f04534-33b0-54c3-9972-7aaf86096eff"", ""word_count"": 272, ""uri"": ""nyt://article/a8f04534-33b0-54c3-9972-7aaf86096eff""}"
2015-03-04,"{""abstract"": ""Opdivo, from Bristol-Myers Squibb, which harnesses the body\u2019s own immune system to attack tumors, was approved after strong results in a study."", ""web_url"": ""https://www.nytimes.com/2015/03/05/business/lung-cancer-treatment-using-immune-system-wins-fda-approval.html"", ""snippet"": ""Opdivo, from Bristol-Myers Squibb, which harnesses the body\u2019s own immune system to attack tumors, was approved after strong results in a study."", ""lead_paragraph"": ""The first immune-based treatment for lung cancer won approval from the Food and Drug Administration on Wednesday, and it could displace more conventional chemotherapy for certain patients, at least."", ""print_section"": ""B"", ""print_page"": ""10"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Lung Cancer Treatment Using Immune System Wins F.D.A. Approval"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Backs a Lung Cancer Therapy"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Lung Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Melanomas"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-03-04T22:49:31+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e835a4d2-776a-5666-9b20-1c8850a5fb11"", ""word_count"": 627, ""uri"": ""nyt://article/e835a4d2-776a-5666-9b20-1c8850a5fb11""}"
2015-03-16,"{""abstract"": ""The higher offer quickly put an end to Endo\u2019s rival bid, but the added cost, along with the debt Valeant already holds, may hurt the company."", ""web_url"": ""https://www.nytimes.com/2015/03/17/business/dealbook/valeants-sweetened-bid-for-salix-may-have-delivered-2-knockouts.html"", ""snippet"": ""The higher offer quickly put an end to Endo\u2019s rival bid, but the added cost, along with the debt Valeant already holds, may hurt the company."", ""lead_paragraph"": ""The sweetened $11 billion bid by Valeant Pharmaceuticals for Salix Pharmaceuticals may have scored two knockouts. By coming up with an extra 9 percent over its previous offer, the acquisitive drug maker, now backed by the hedge fund executive William A. Ackman, quickly put an end to a rival bid from Endo International. But the extra cash required, and the debt already on its balance sheet, leave Valeant\u2019s business model looking wobbly."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-superJumbo.jpg"", ""height"": 1364, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Valeant\u2019s Sweetened Bid for Salix May Have Delivered 2 Knockouts"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Valeant Pharmaceuticals International Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Salix Pharmaceuticals Ltd"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Endo International PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Ackman, William A"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-03-16T21:45:43+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/38f246e6-9e8f-599a-8c48-69100ddea562"", ""word_count"": 387, ""uri"": ""nyt://article/38f246e6-9e8f-599a-8c48-69100ddea562""}"
2015-05-07,"{""abstract"": ""Johnson & Johnson named the bioethicist Arthur L. Caplan to create a panel to decide on patients\u2019 requests for lifesaving medicines before they are approved."", ""web_url"": ""https://www.nytimes.com/2015/05/07/business/company-creates-bioethics-panel-on-trial-drugs.html"", ""snippet"": ""Johnson & Johnson named the bioethicist Arthur L. Caplan to create a panel to decide on patients\u2019 requests for lifesaving medicines before they are approved."", ""lead_paragraph"": ""Johnson & Johnson has appointed a nationally known bioethicist to create a panel that will make decisions about patients\u2019 requests for potentially lifesaving medicine, responding to an emotional debate over whether companies should allow desperately ill people to have access to the drugs before they are approved."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/07/business/Ethics/Ethics-articleLarge.jpg"", ""height"": 936, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/05/07/business/Ethics/Ethics-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 936}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/07/business/Ethics/Ethics-jumbo.jpg"", ""height"": 984, ""width"": 631, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/07/business/Ethics/Ethics-superJumbo.jpg"", ""height"": 984, ""width"": 631, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/07/business/Ethics/Ethics-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/05/07/business/Ethics/Ethics-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/07/business/Ethics/Ethics-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Company Creates Bioethics Panel on Trial Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Company Creates Panel for Access to Trial Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Caplan, Arthur L"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""New York University Langone Medical Center"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Chimerix Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Ethics and Official Misconduct"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2015-05-07T04:01:15+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/33bf8157-acaf-5847-8be6-234e9850e1c6"", ""word_count"": 1614, ""uri"": ""nyt://article/33bf8157-acaf-5847-8be6-234e9850e1c6""}"
2015-05-29,"{""abstract"": ""A study sheds light on why the new medicines seem to work for some cancers and not others."", ""web_url"": ""https://www.nytimes.com/2015/05/30/business/new-class-of-drugs-shows-more-promise-in-treating-cancer.html"", ""snippet"": ""A study sheds light on why the new medicines seem to work for some cancers and not others."", ""lead_paragraph"": ""A new drug that unleashes the body\u2019s immune system to attack tumors can prolong the lives of people with the most common form of lung cancer, doctors reported on Friday, the latest example of the significant results being achieved by this new class of medicines."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/30/business/30lung-web/30lung-web-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/05/30/business/30lung-web/30lung-web-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/30/business/30lung-web/30lung-web-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/30/business/30lung-web/30lung-web-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/30/business/30lung-web/30lung-web-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/05/30/business/30lung-web/30lung-web-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/05/30/business/30lung-web/30lung-web-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""New Class of Drugs Shows More Promise in Treating Cancer"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""New Promise in New Class of Drugs for Cancer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lung Cancer"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""New England Journal of Medicine"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tumors"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Immune System"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Colon and Colorectal Cancer"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prostate Cancer"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMERICAN SOCIETY OF CLINICAL ONCOLOGY"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 12, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Skin Cancer"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2015-05-29T18:00:49+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/bf667393-fcb4-5b3c-ab99-781cfe3fa4da"", ""word_count"": 1109, ""uri"": ""nyt://article/bf667393-fcb4-5b3c-ab99-781cfe3fa4da""}"
2016-01-11,"{""abstract"": ""Some pharmaceutical companies will form the National Immunotherapy Coalition to rapidly test various combinations of promising new types of cancer drugs."", ""web_url"": ""https://www.nytimes.com/2016/01/12/business/drug-companies-to-try-a-unified-front-against-cancer.html"", ""snippet"": ""Some pharmaceutical companies will form the National Immunotherapy Coalition to rapidly test various combinations of promising new types of cancer drugs."", ""lead_paragraph"": ""SAN FRANCISCO \u2014 Some leading pharmaceutical companies are joining forces in an effort to speed the testing of new types of cancer drugs that harness the body\u2019s immune system to battle tumors."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-articleLarge.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 419}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-jumbo.jpg"", ""height"": 716, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-superJumbo.jpg"", ""height"": 1432, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Drug Companies to Try a Unified Front Against Cancer"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Soon-Shiong, Patrick"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Celgene Corporation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2016-01-11T15:46:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e37fcae4-ae54-52e9-923d-774b4b8ee48f"", ""word_count"": 505, ""uri"": ""nyt://article/e37fcae4-ae54-52e9-923d-774b4b8ee48f""}"
2016-08-05,"{""abstract"": ""Investors wiped off billions in value after Bristol\u2019s cancer drug trial failed. The stumble will allow its more cautious rival to clean up."", ""web_url"": ""https://www.nytimes.com/2016/08/06/business/dealbook/bristol-myers-squibbs-hubris-cost-it-21-billion.html"", ""snippet"": ""Investors wiped off billions in value after Bristol\u2019s cancer drug trial failed. The stumble will allow its more cautious rival to clean up."", ""lead_paragraph"": ""Bristol-Myers Squibb has suffered a $21 billion self-inflicted wound."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/08/06/business/06DRUG/06DRUG-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-articleLarge.jpg"", ""height"": 401, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/08/06/business/06DRUG/06DRUG-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 401}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-jumbo.jpg"", ""height"": 684, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/06/business/06DRUG/06DRUG-superJumbo.jpg"", ""height"": 1369, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Bristol-Myers Squibb\u2019s Hubris Cost It $21 Billion"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lung Cancer"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2016-08-05T18:03:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/22153e7e-a684-5867-a538-88f5fd60e091"", ""word_count"": 413, ""uri"": ""nyt://article/22153e7e-a684-5867-a538-88f5fd60e091""}"
